Browsing by Author "Telles-Correia, Diogo"
Now showing 1 - 8 of 8
Results Per Page
Sort Options
- Assessing the management of excessive daytime sleepiness by napping benefitsPublication . Murillo-Rodríguez, Eric; Yamamoto, Tetsuya; Monteiro, Diogo; Budde, Henning; Rocha, Nuno Barbosa; Cid, Luis; Teixeira, Diogo S.; Telles-Correia, Diogo; Veras, André Barciela; Machado, Sérgio; Imperatori, Claudio; Torterolo, PabloPurpose Demanding lifestyle characterized by extended working hours, shift work schedules as well as excessive use of mobile gadgets leads to the disruption of the circadian and homeostatic factors affecting the sleep quality of individuals. As consequence, subjects complain of suffering several sleep disorders some of them characterized by inducing excessive daytime sleepiness (EDS). Currently, the therapeutic approaches for managing EDS include medication, promotion of sleep hygiene, cognitive and behavioral therapy or using of continuous positive airway pressure machine. In this review, we propose the posology of the personalized sleep medicine by the prescription of naps for treating EDS. Methods This review included the online search in PubMed and manual review of articles (basic and clinical trials) of a range of personalized medicine potentially associated to factors of dosage in areas such as nutrition, sports and sleep. Articles in English were identified and subsequently analyzed for consideration for this review. Results Current evidence has demonstrated that naps exert positive outcomes for individuals complaining with EDS. The dosage of naps might follow similar procedures as reported for personalized interventions in diets or exercise programs (by taking the right dose, at the proper time, with a recommended frequency) which have demonstrated successfully results. Conclusions The management of EDS may include the personalized sleep medicine considering the prescription of dosage of naps.
- Correlation between levels of physical activity and anxiety and in patients with binge-eating disorderPublication . Da Silva Freire, Andrea; Dos Santos, David; Vaz, Ana; Lima, João Lucas; Axt, Glaciane; Murillo-Rodriguez, Eric; Monteiro, Diogo; Cid, Luis; Machado, Sergio; Telles-Correia, DiogoBinge-eating disorder (BED) is linked to several psychiatric disorders, such as anxiety disorders. Approximately 50-60% of BED patients are resistant to the traditional treatments available, and thus, strategies supporting the treatment of BED are needed, such as physical activity (PA). It seems to be an interesting strategy to reduce BED and anxiety symptoms. Thus, since PA has a role in reducing BED episodes and improving anxiety symptoms, then more research is needed to clarify the role of PA on BED, as correlations between anxiety-BED and anxiety-PA are established. Therefore, our aim is to examine the relationship between PA and anxiety in patients with BED. Thirty two patients we submitted to psychological and PA questionnaires. A Pearson's correlation coefficient and a multiple linear regression analysis were performed to relate eating disorder behaviour, anxiety and PA. The correlation coefficients between the dimensions of BED and anxiety were almost all significant (except restriction), positive and moderate (p<0.001). Thus, the higher the eating disorder values, the higher the anxiety levels (p<0.01). In conclusion, our findings support that PA correlates with anxiety in patients with BED, suggesting that PA may decrease symptoms, such as the appetite, weight and body shape concerns.
- Exercise is medicine: a new perspective for health promotion in bipolar disorderPublication . Sá Filho, Alberto Souza; Cheniaux, Elie; de Paula, Carolina Cavalcante; Murillo-Rodriguez, Eric; Teixeira, Diogo; Monteiro, Diogo; Cid, Luis; Yamamoto, Tetsuya; Telles-Correia, Diogo; Imperatori, Claudio; Budde, Henning; Machado, SergioSimilar effects in reducing the symptoms of the mood disorder are reported in the literature compared the action of drugs and aerobic exercise sessions, demonstrating the potential of exercise in the control and mood stabilization. Therefore, there are many reasons to believe that the increased cardiorespiratory fitness (VO2max) can be an important means of protection and a reducing potential of physical and mental damage in bipolar disorders (BD). This review will highlight the current pattern of response of exercise on the pathophysiology of BD, relating the possible mechanisms, and hypotheses based on exercises.
- Impact of aerobic exercise on anxiety and neurobiological mechanisms in panic disorder: a mini-reviewPublication . Machado, Sérgio; Lima, João Lucas; Teixeira, Diogo Santos; Monteiro, Diogo; Cid, Luis; Neto, Sílvio; Maranhão, Geraldo Neto; Murillo-Rodriguez, Eric; Telles-Correia, DiogoIn the last few decades exercise has been explored as a potential tool to reduce symptoms experienced by patients with panic disorder (PD). This review aims to present the effects of exercise interventions on panic severity, and anxiety symptoms of patients with PD. A literature search was conducted using PubMeb and ISI Web of Science databases, with the search terms panic disorder and aerobic exercise, exercise therapy, physical fitness, physical activity, aerobic training. Acute studies suggest that exercise immediately increases panic-related symptoms, but allows the reduction of artificially induced increase panic attacks and anxiety. There is still no clear evidence indicating that regular exercise programs reduce panic-related symptoms, but it seems that this intervention is effective to improve global anxiety measures. In addition, exercise seems to induce neurobiological effects that influence on several neural mechanisms related to anxiety disorders, such as increase of monoamine levels and brain-derived neurotrophic factor (BDNF).Both aerobic exercise and regular aerobic exercise seem to be an appropriate intervention to promote improvements in the severity of anxiety symptoms in PD patients. It is suggested a greater control in the prescription of aerobic exercise, to bring promising answers regarding the efficacy of exercise on symptoms in patients with PD.
- Sleep and Neurochemical Modulation by DZNep and GSK-J1: Potential Link With Histone Methylation StatusPublication . Murillo-Rodríguez, Eric; Arankowsky-Sandoval, Gloria; Barros, Jorge Aparecido; Rocha, Nuno Barbosa; Yamamoto, Tetsuya; Machado, Sérgio; Budde, Henning; Telles-Correia, Diogo; Monteiro, Diogo; Cid, Luis; Veras, André BarcielaHistone methylation/demethylation plays an important modulatory role in chromatin restructuring, RNA transcription and is essential for controlling a plethora of biological processes. Due to many human diseases have been related to histone methylation/demethylation, several compounds such as 3-deazaneplanocin A (DZNep) or 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-Alanine (GSK-J1), have been designed to inhibit histone methylase or suppress histone demethylase, respectively. In the present study, we investigated the effects on the sleep-wake cycle and sleep-related neurochemical levels after systemic injections of DZNep or GSK-J1 given during the light or dark phase in rats. DZNep dose-dependently (0.1, 1.0, or 10 mg/kg, i.p.) prolonged wakefulness (W) duration while decreased slow wave sleep (SWS) and rapid eye movement sleep (REMS) time spent during the lights-on period with no changes observed in dark phase. In opposite direction, GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.) injected at the beginning of the lights-on period induced no statistical changes in W, SWS, or REMS whereas if administered at darkness, we found a diminution in W and an enhancement in SWS and REMS. Finally, brain microdialysis experiments in freely moving animals were used to evaluate the effects of DZNep or GSK-J1 treatments on contents of sleep-related neurochemicals. The results showed that DZNep boosted extracellular levels of dopamine, norepinephrine, epinephrine, serotonin, adenosine, and acetylcholine if injected at the beginning of the lights-on period whereas GSK-J1 exerted similar outcomes but when administered at darkness. In summary, DZNep and GSK-J1 may control the sleep-wake cycle and sleep-related neurochemicals through histone methylation/demethylation activity.
- Sleep Disorders and GenesPublication . Murillo-Rodríguez, Eric; Yamamoto, Tetsuya; Veras, André Barciela; Rocha, Nuno Barbosa; Telles-Correia, Diogo; Budde, Henning; Machado, Sérgio; Monteiro, Diogo; Torterolo, PabloThe sleep-wake cycle is a neurobiological phenomenon that shows intervals of activity alternating with restfulness that appears with a periodicity approximating the 24h day-night cycle. The sleep-wake cycle is under the control of diverse neuroanatomical and neurochemical systems, including monoaminergic, cholinergic, adenosinergic among many other systems. In addition, neuroanatomical centers linked to sleep promotion, such as hypothalamus, project to the cerebral cortex, subcortical relays and brainstem. In addition, the sleep-wake cycle has been associated to aberrant features known as sleep disorders. Here, we will discuss the role of specific gene expression on sleep disturbances. Given the expansion of the knowledge in the sleep-wake cycle area, it is indeed ambitious to describe all the genetics involved in the sleep modulation. However, in this chapter we reviewed the current understanding of the sleep disorders and gene expression.
- The Endocannabinoid System May Modulate Sleep Disorders In AgingPublication . Murillo-Rodríguez, Eric; Budde, Henning; Veras, André Barciela; Rocha, Nuno Barbosa; Telles-Correia, Diogo; Monteiro, Diogo; Cid, Luis; Yamamoto, Tetsuya; Machado, Sérgio; Torterolo, PabloAging is an inevitable process that involves changes along life in multiple neurochemical, neuroanatomical, hormonal systems, and many others. In addition, these biological modifications lead to an increase in age-related sickness such as cardiovascular diseases, osteoporosis, neurodegenerative disorders, and sleep disturbances, among others that affect activities of daily life. Demographic projections have demonstrated that aging will increase its worldwide rate in the coming years. The research on chronic diseases of the elderly is important to gain insights into this growing global burden. Novel therapeutic approaches aimed for treatment of age-related pathologies have included the endocannabinoid system as an effective tools since this biological system shows beneficial effects in preclinical models. However, and despite these advances, little has been addressed in the arena of the endocannabinoid system as option for treating sleep disorders in aging since experimental evidence suggests that some elements of the endocannabinoid system modulate the sleep-wake cycle. This article addresses this less-studied field, focusing on the likely perspective of the implication of the endocannabinoid system in the regulation of sleep problems reported in aged. We conclude that beneficial effects regarding the putative efficacy of the endocannabinoid system as therapeutic tools in aging is either inconclusive or still missing.
- The retinoid X receptor: a nuclear receptor that modulates the sleep-wake cycle in ratsPublication . Murillo-Rodríguez, Eric; Millán-Aldaco, Diana; Arankowsky-Sandoval, Gloria; Yamamoto, Tetsuya; Cid, Luis; Monteiro, Diogo; Rocha, Nuno Barbosa; Telles-Correia, Diogo; Teixeira, Diogo S.; Veras, André Barciela; Budde, Henning; Machado, Sérgio; Imperatori, Claudio; Torterolo, PabloRationale The nuclear receptor retinoid X receptor (RXR) belongs to a nuclear receptor superfamily that modulates diverse functions via homodimerization with itself or several other nuclear receptors, including PPARα. While the activation of PPARα by natural or synthetic agonists regulates the sleep-wake cycle, the role of RXR in the sleep modulation is unknown. Objectives We investigated the effects of bexarotene (Bexa, a RXR agonist) or UVI 3003 (UVI, a RXR antagonist) on sleep, sleep homeostasis, levels of neurochemical related to sleep modulation, and c-Fos and NeuN expression. Methods The sleep-wake cycle and sleep homeostasis were analyzed after application of Bexa or UVI. Moreover, we also evaluated whether Bexa or UVI could induce effects on dopamine, serotonin, norepinephrine epinephrine, adenosine, and acetylcholine contents, collected from either the nucleus accumbens or basal forebrain. In addition, c-Fos and NeuN expression in the hypothalamus was determined after Bexa or UVI treatments. Results Systemic application of Bexa (1 mM, i.p.) attenuated slow-wave sleep and rapid eye movement sleep. In addition, Bexa increased the levels of dopamine, serotonin, norepinephrine epinephrine, adenosine, and acetylcholine sampled from either the nucleus accumbens or basal forebrain. Moreover, Bexa blocked the sleep rebound period after total sleep deprivation, increased in the hypothalamus the expression of c-Fos, and decreased NeuN activity. Remarkably, UVI 3003 (1 mM, i.p.) induced opposite effects in sleep, sleep homeostasis, neurochemicals levels, and c-Fos and NeuN activity. Conclusions The administration of RXR agonist or antagonist significantly impaired the sleep-wake cycle and exerted effects on the levels of neurochemicals related to sleep modulation. Moreover, Bexa or UVI administration significantly affected c-Fos and NeuN expression in the hypothalamus. Our findings highlight the neurobiological role of RXR on sleep modulation.